Pyoderma gangrenosumhttps://en.wikipedia.org/wiki/Pyoderma_gangrenosum
☆ ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ. ຢູ່ຂາຄົນມີບາດແຜຖະຫຼອກຕາມຕົນຕົວ.
relevance score : -100.0%
References Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments 35606650 NIH
Pyoderma gangrenosum ເປັນສະພາບຜິວໜັງທີ່ຫາຍາກທີ່ເຮັດໃຫ້ເກີດແຜເປັນບາດແຜທີ່ມີຂອບສີແດງ ຫຼື ສີມ່ວງ. ມັນໄດ້ຖືກຈັດປະເພດເປັນພະຍາດອັກເສບແລະເປັນສ່ວນຫນຶ່ງຂອງກຸ່ມທີ່ເອີ້ນວ່າ neutrophilic dermatoses. ສາເຫດຂອງ pyoderma gangrenosum ມີຄວາມຊັບຊ້ອນ, ກ່ຽວຂ້ອງກັບບັນຫາທີ່ມີທັງພູມຕ້ານທານຈາກກໍາເນີດແລະການປັບຕົວຢູ່ໃນຄົນທີ່ມີເຊື້ອພັນທຸກໍາ. ບໍ່ດົນມານີ້, ນັກຄົ້ນຄວ້າໄດ້ສຸມໃສ່ການຮາກຜົມເປັນຈຸດເລີ່ມຕົ້ນຂອງພະຍາດ.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma Gangrenosum: Treatment Options 37610614 NIH
Pyoderma gangrenosum ເປັນສະພາບຜິວໜັງທີ່ຫາຍາກເຮັດໃຫ້ເກີດບາດແຜທີ່ເຈັບປວດທີ່ສຸດ. ໃນຂະນະທີ່ພວກເຮົາບໍ່ເຂົ້າໃຈຢ່າງຄົບຖ້ວນກ່ຽວກັບສາເຫດຂອງມັນ, ພວກເຮົາຮູ້ວ່າມັນກ່ຽວຂ້ອງກັບກິດຈະກໍາທີ່ເພີ່ມຂຶ້ນຂອງຈຸລັງພູມຕ້ານທານບາງຢ່າງ. ການປິ່ນປົວພະຍາດແມ່ນບໍ່ງ່າຍດາຍ. ພວກເຮົາມີຢາຕ່າງໆທີ່ສະກັດກັ້ນລະບົບພູມຕ້ານທານຫຼືດັດແປງກິດຈະກໍາຂອງມັນ. ຄຽງຄູ່ກັບການເຫຼົ່ານີ້, ພວກເຮົາຍັງສຸມໃສ່ການປິ່ນປົວບາດແຜແລະການຄຸ້ມຄອງອາການເຈັບປວດ. Corticosteroids ແລະ cyclosporine ມັກຈະເປັນທາງເລືອກທໍາອິດສໍາລັບການປິ່ນປົວ, ແຕ່ບໍ່ດົນມານີ້, ມີການຄົ້ນຄວ້າເພີ່ມເຕີມກ່ຽວກັບການນໍາໃຊ້ການປິ່ນປົວດ້ວຍທາງຊີວະພາບເຊັ່ນ TNF-α inhibitors. ຊີວະວິທະຍາເຫຼົ່ານີ້ແມ່ນເປັນທີ່ນິຍົມຫຼາຍຂຶ້ນ, ໂດຍສະເພາະໃນຄົນເຈັບທີ່ມີສະພາບອັກເສບອື່ນໆ, ແລະພວກມັນຖືກນໍາໃຊ້ໃນຂະບວນການຂອງພະຍາດກ່ອນຫນ້ານີ້.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.